Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
LENZ Therapeutics, Inc. - Common Stock
(NQ:
LENZ
)
3.565
-0.225 (-5.94%)
Delayed Quote
Updated: 2:26 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about LENZ Therapeutics, Inc. - Common Stock
< Previous
1
2
Next >
LENZ Therapeutics (LENZ) Q2 2026 Earnings Call Transcript
↗
August 19, 2026
Prescription growth surged 45% in July after telehealth launch.
Via
The Motley Fool
Topics
Earnings
LENZ Therapeutics Q2 Earnings Call Highlights
↗
August 11, 2026
LENZ Therapeutics (NASDAQ:LENZ) reported second-quarter revenue of $5.5 million as it continued the commercial launch of VIZZ, citing modest quarterly growth and a pickup in prescription activity...
Via
MarketBeat
Topics
Earnings
Alpha Wave Global Reduces RadNet Stake, According to Recent SEC Filing
↗
June 02, 2026
RadNet runs a large outpatient imaging network and is building DeepHealth, its AI radiology platform. The upside is clearer if advanced imaging growth and digital health expansion can develop without...
Via
The Motley Fool
Topics
Artificial Intelligence
Regulatory Compliance
LENZ Therapeutics (NASDAQ:LENZ) Q1 Report Shows Revenue Beat But Deepening Losses Sink Stock
↗
May 11, 2026
Via
Chartmill
LENZ Therapeutics Inc (NASDAQ:LENZ) Reports Q4 Revenue Miss and Wider Loss Following VIZZ Launch
↗
March 24, 2026
Via
Chartmill
Earnings Scheduled For November 5, 2025
↗
November 05, 2025
Via
Benzinga
Earnings Scheduled For May 7, 2025
↗
May 07, 2025
Via
Benzinga
Alpha Wave Global Initiates COPT Defense Properties Position, According to Recent SEC Filing
↗
May 27, 2026
COPT Defense Properties serves defense and intelligence tenants near secure government hubs. Investors will be closely watching whether that niche can keep supporting growth while much of the office...
Via
The Motley Fool
Topics
Regulatory Compliance
LENZ Therapeutics Q1 Earnings Call Highlights
↗
May 11, 2026
LENZ Therapeutics (NASDAQ:LENZ) reported first-quarter 2026 results that showed continued prescription growth for its presbyopia eye drop VIZZ, while management acknowledged that new patient adoption...
Via
MarketBeat
Topics
Earnings
Lenz (LENZ) Q1 2026 Earnings Call Transcript
↗
May 11, 2026
Lenz (LENZ) Q1 2026 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Why Lenz Therapeutics Stock Plummeted by Almost 20% This Week
↗
March 27, 2026
It failed to meet expectations for its final quarter of 2025.
Via
The Motley Fool
Why Lenz Therapeutics Stock Crashed Today
↗
March 24, 2026
Is it time to throw away your reading glasses? Maybe not just yet.
Via
The Motley Fool
Top Wall Street Forecasters Revamp LENZ Therapeutics Expectations Ahead Of Q4 Earnings
↗
March 23, 2026
LENZ Therapeutics (NASDAQ:LENZ) to release Q4 earnings on 3/24. Analysts expect loss of 90 cents/share. Stock gained 5% on Monday. Analyst ratings and accuracy rates available on Benzinga.
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
↗
November 05, 2025
Via
Benzinga
LENZ Therapeutics Inc (NASDAQ:LENZ) Reports Q3 2025 Revenue Beat and Progress on VIZZ Launch
↗
November 05, 2025
LENZ Therapeutics Q3 2025 results show an 80% revenue beat and narrower loss as it launches its new FDA-approved vision treatment, VIZZ™.
Via
Chartmill
Major Insider Sale Casts Shadow on LENZ Therapeutics' Valuation
September 27, 2025
San Diego, CA – September 27, 2025 – LENZ Therapeutics (NASDAQ: LENZ) is facing heightened scrutiny this week following a significant insider share sale by a major shareholder, Versant Venture Capital...
Via
MarketMinute
Topics
Artificial Intelligence
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
August 11, 2025
Via
Benzinga
Why International Money Express Shares Are Trading Higher By Around 54%; Here Are 20 Stocks Moving Premarket
↗
August 11, 2025
Via
Benzinga
LENZ Therapeutics' Eye Drop Scores First FDA Approval For Age-Related Blurred Vision Condition Impacting 128 Million People
↗
August 01, 2025
LENZ Therapeutics' VIZZ earns FDA approval as the first aceclidine-based eye drop to treat presbyopia, with U.S. launch expected in Q4 2025.
Via
Benzinga
Lenz (LENZ) Q2 Revenue Jumps 604%
↗
July 31, 2025
Via
The Motley Fool
12 Health Care Stocks Moving In Friday's After-Market Session
↗
May 02, 2025
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
↗
March 19, 2025
Via
Benzinga
Earnings Scheduled For March 19, 2025
↗
March 19, 2025
Via
Benzinga
LENZ Therapeutics' Investigational Drug For Age-Related Blindness Aces Pivotal China Trial, Analyst Says Data Readout May Strengthen Position For Ex-U.S. Partnerships
↗
October 28, 2024
LENZ Therapeutics and Corxel Pharmaceuticals announced Phase 3 data for LNZ100, showing significant presbyopia improvements, supporting potential FDA approval.
Via
Benzinga
Why LENZ Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
↗
October 28, 2024
Via
Benzinga
Why LENZ Therapeutics Stock Hit A New 52-Week High Today
↗
October 21, 2024
Lenz Therapeutics shares hit a new 52-week high during Monday's session. The company announced the FDA accepted its new drug application.
Via
Benzinga
LENZ Stock Earnings: LENZ Therapeutics Misses EPS for Q1 2024
↗
August 26, 2024
LENZ stock results show that LENZ Therapeutics missed analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Why Skye Bioscience Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session
↗
June 10, 2024
Via
Benzinga
ICC Holdings, Diamond Offshore Drilling, CrowdStrike And Other Big Stocks Moving Higher On Monday
↗
June 10, 2024
Via
Benzinga
Blindness-Focused LENZ Therapeutics' Investigational Eye Drop Ready To Revolutionize Presbyopia Landscape, Analyst Says
↗
April 10, 2024
Advances in presbyopia treatment with LENZ Therapeutics' LNZ100. Clinically proven to enhance near-vision for up to 10 hours, it offers a promising alternative to reading glasses. Analysts predict a...
Via
Benzinga
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
